Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer LAUSANNE, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, today...

Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development  Hevolution Foundation and Dolby Family Ventures join ND Capital as additional institutional investors bringing Series A funding to a total of $30.7M (CHF28.3M)Vandria’s lead CNS compound VNA-318 is a...

Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liverInnosuisse grant totalling CHF 2.5M (€2.7M) to support early clinical...

Vandria Announces $20.6M (CHF18M) Series A Financing Led by ND Capital to Drive CNS Clinical Program and Mitochondrial Therapeutics Platform Vandria emerges from stealth announcing its $20.6M (CHF18M) Series A financing led by ND CapitalLead candidate VNA-318 is a clinic-ready, brain-penetrant, mitophagy inducer shown to improve memory and...